Document is current
Any future updates will be listed below
-
Authors
Ahmed, Jibran
Knisely, Anne
Stephen, Bettzy
Yang, Yali
Song, Juhee
Alshawa, Anas
Zarifa, Abdulrazzak
Morris, Van
Javle, Milind
Wolff, Robert A
Meric-Bernstam, Funda
Pant, Shubham
Rodon, Jordi
Naing, Aung
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03217747 at ClinicalTrials.govDocuments that mention this clinical trial
191 Tumor microenvironment changes after treatment with avelumab combinations in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2025-sitc2025.0191
8 Immune correlates associated with clinical outcomes in patients with advanced malignancies treated with avelumab and OX40 agonist
https://doi.org/10.1136/jitc-2020-sitc2020.0008
584 Phase I/II study to evaluate the safety and tolerability of avelumab in combination with other anti-cancer therapies in patients with advanced malignancies
https://doi.org/10.1136/jitc-2023-sitc2023.0584
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2022-005471
- License Information
